MET and non-small cell lung carcinoma: Tepotinib is a once daily, orally available, highly selective and potent MET tyrosine kinase inhibitor (12,13) that was approved in March 2020 by the Japanese Ministry of Health, Labour and Welfare for the line-agnostic treatment of patients with unresectable advanced or recurrent NSCLC with MET exon 14 skipping.